Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.42 -1.6%	$1.92	$0.90 ▼ $3.42	$87.54M	0.94	70,195 shs	15,244 shs
IGMS IGM Biosciences	$1.30 -4.1%	$1.24	$0.92 ▼ $22.50	$77.41M	0.48	382,808 shs	1.70 million shs
MGX Metagenomi	$2.10 +0.7%	$1.66	$1.23 ▼ $5.38	$78.31M	-0.38	872,627 shs	545,587 shs
OTLC Oncotelic Therapeutics	$0.05 -17.2%	$0.05	$0.02 ▼ $0.07	$19.60M	-0.75	116,201 shs	154,016 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	+7.42%	+13.36%	+31.55%	+108.47%	-32.79%
IGMS IGM Biosciences	-0.74%	+1.50%	+11.57%	+13.45%	-86.98%
MGX Metagenomi	-7.56%	+8.90%	+45.45%	+40.54%	-57.81%
OTLC Oncotelic Therapeutics	0.00%	+11.54%	+17.41%	+0.87%	+123.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	2.7456 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	0.0
IGMS IGM Biosciences	4.6326 of 5 stars	3.0	5.0	0.0	4.6	3.3	3.3	0.6
MGX Metagenomi	2.8876 of 5 stars	3.5	4.0	0.0	0.0	2.1	1.7	0.6
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$9.00	271.90% Upside
IGMS IGM Biosciences	1.90	Reduce	$5.50	324.71% Upside
MGX Metagenomi	3.00	Buy	$13.00	520.53% Upside
OTLC Oncotelic Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OTLC, MGX, ARMP, and IGMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	ARMP Armata Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$5.17M	16.94	N/A	N/A	($1.33) per share	-1.82
IGMS IGM Biosciences	$2.68M	28.87	N/A	N/A	$0.82 per share	1.58
MGX Metagenomi	$52.29M	1.50	N/A	N/A	$6.28 per share	0.33
OTLC Oncotelic Therapeutics	$70K	279.97	$0.00 per share	11.30	$0.02 per share	2.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$18.92M	-$1.64	N/A	N/A	N/A	N/A	N/A	-25.06%	8/12/2025 (Estimated)
IGMS IGM Biosciences	-$195.79M	-$3.27	N/A	N/A	N/A	-7,417.79%	-317.97%	-71.43%	8/13/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.11	N/A	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)
OTLC Oncotelic Therapeutics	-$4.52M	-$0.01	N/A	∞	N/A	N/A	-14.16%	-4.41%	N/A

Latest OTLC, MGX, ARMP, and IGMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	IGMS IGM Biosciences	-$0.12	N/A	N/A	N/A	$0.40 million	N/A
8/13/2025	Q2 2025	MGX Metagenomi	-$0.62	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	ARMP Armata Pharmaceuticals	-$0.39	N/A	N/A	N/A	$1.38 million	N/A
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	0.12	0.12
IGMS IGM Biosciences	N/A	5.71	5.71
MGX Metagenomi	N/A	5.85	5.85
OTLC Oncotelic Therapeutics	N/A	0.01	0.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
IGMS IGM Biosciences	42.79%
MGX Metagenomi	N/A
OTLC Oncotelic Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	84.50%
IGMS IGM Biosciences	57.00%
MGX Metagenomi	17.80%
OTLC Oncotelic Therapeutics	39.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	70	36.19 million	5.61 million	Not Optionable
IGMS IGM Biosciences	190	59.78 million	25.70 million	Optionable
MGX Metagenomi	236	37.38 million	30.73 million	N/A
OTLC Oncotelic Therapeutics	20	408.29 million	248.16 million	Not Optionable

OTLC, MGX, ARMP, and IGMS Headlines

Recent News About These Companies

Oncotelic Therapeutics, Inc. (OTLC) - Yahoo Finance

June 27, 2025 | nz.finance.yahoo.com

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

June 25, 2025 | globenewswire.com

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

April 22, 2025 | globenewswire.com

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023

April 16, 2025 | globenewswire.com

Oncotelic Therapeutics Inc (OTLC)

April 10, 2025 | nasdaq.com

Oncotelic Therapeutics Delays Yearly Report Filing

March 31, 2025 | tipranks.com

Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI

March 31, 2025 | globenewswire.com

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

March 25, 2025 | globenewswire.com

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon

February 25, 2025 | globenewswire.com

Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference

February 13, 2025 | globenewswire.com

Oncotelic Therapeutics Implements PDAOAI Platform

December 31, 2024 | globenewswire.com

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

November 6, 2024 | globenewswire.com

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

October 28, 2024 | finance.yahoo.com

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

October 24, 2024 | finance.yahoo.com

Russia faces new wave of drop in clinical trials for new drugs

September 30, 2024 | thepharmaletter.comT

Alibaba rises on report it will charge software service fee

July 29, 2024 | uk.finance.yahoo.com

Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence

July 29, 2024 | globenewswire.com

ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY

June 11, 2024 | globenewswire.com

ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING

May 30, 2024 | globenewswire.com

ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING

May 20, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLC, MGX, ARMP, and IGMS Company Descriptions

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$2.42 -0.04 (-1.63%)

As of 02:45 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

IGM Biosciences NASDAQ:IGMS

$1.30 -0.06 (-4.07%)

As of 02:46 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Metagenomi NASDAQ:MGX

$2.10 +0.02 (+0.72%)

As of 02:46 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Oncotelic Therapeutics OTCMKTS:OTLC

$0.05 -0.01 (-17.24%)

As of 01:38 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time